Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...
Ira is able to live life with a special zest and energy that's hard to keep up with! But as Ira grew bigger, so did her ...
April 30 (Reuters) - (This April 30 story has been corrected to say it was Neurocrine's movement disorder drug, not Huntington's disease drug, in the headline and to remove the reference to chorea in ...
A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr ...
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...
Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results